A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Sepetaprost (Primary) ; Sepetaprost (Primary) ; Latanoprost; Latanoprost
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ono Pharmaceutical
- 22 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Nov 2014 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 04 Jun 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.